CD19 and non-Hodgkin lymphoma: The results of autologous CD19-targeted second-generation CAR T cells treatment obtained so far in indolent NHL patients have been recently updated.51 Of 15 patients enrolled, eight achieved complete remissions (CRs), four achieved partial remissions, one had stable lymphoma, and two were not evaluable for response.